Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26328803 | 0.94 | MAPK1 (0.38) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL26328801 | 0.94 | RAB9A (0.49) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL26330111 | 0.94 | NPC1 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL25439968 | 0.94 | MAPT (0.45) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL25439789 | 0.92 | POLB (0.48) | LMNARAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL5375326 | 0.92 | LMNA (0.49) | MAPK1LMNARAB9AALDH1A1TSHR | |
| SCHEMBL25440125 | 0.91 | APOBEC3A (0.49) | CA1CA2ESR2RAB9ASMN1; SMN2 | |
| SCHEMBL25439927 | 0.89 | KDM4E (0.47) | MAPK1LMNACYP1A2RAB9ASMN1; SMN2 | |
| SCHEMBL25439955 | 0.88 | ADRB2 (0.49) | CA1CA2ALDH1A1TSHRTDP1 | |
| SCHEMBL25440024 | 0.88 | ADRB2 (0.51) | ALDH1A1MEN1KMT2AATMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | UNIVERSITY OF DELAWARE (US) | 2023-09-26 | — | — | US | disclosed |
| US-11542268-B2 | Cationically curable compositions with latent reducing agent demonstrating low cure temperature | HENKEL AG & CO. KGAA (DE) | 2023-01-03 | — | — | US | disclosed |
| US-20210107915-A1 | CATIONICALLY CURABLE COMPOSITIONS WITH LATENT REDUCING AGENT DEMONSTRATING LOW CURE TEMPERATURE | HENKEL AG & CO. KGAA (DE) | 2021-04-15 | — | — | US | disclosed |
| WO-2020006159-A1 | CATIONICALLY CURABLE COMPOSITIONS WITH LATENT REDUCING AGENT DEMONSTRATING LOW CURE TEMPERATURE | Henkel IP & Holding GmbH (DE) | 2020-01-02 | — | — | WO | disclosed |
| WO-2014152543-A2 | OXETANE-CONTAINING COMPOUNDS AND COMPOSITIONS THEREOF | Henkel IP & Holding GmbH (DE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140264165-A1 | OXETANE-CONTAINING COMPOUNDS AND COMPOSITIONS THEREOF | HENKEL CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140264165-A1 | OXETANE-CONTAINING COMPOUNDS AND COMPOSITIONS THEREOF | HENKEL CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140209951-A1 | OXETANE-CONTAINING COMPOUNDS AND COMPOSITIONS THEREOF | Henkel IP & Holding GmbH (DE) | 2014-07-31 | — | — | US | disclosed |
| US-20140209951-A1 | OXETANE-CONTAINING COMPOUNDS AND COMPOSITIONS THEREOF | Henkel IP & Holding GmbH (DE) | 2014-07-31 | — | — | US | disclosed |
| WO-2013049154-A2 | OXETANE-CONTAINING COMPOUNDS AND COMPOSITIONS THEREOF | HENKEL AG & CO. KGAA (DE) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | TST, CYP4F8, CYP4Z1 | ESR1 2610/4885CA12 269/4885CA1 504/4885 |
| US-11542268-B2 | Cationically curable compositions with latent reducing agent demonstrating low cure temperature | CHIT1, SGMS2, LTA | ESR1 3732/4885CA12 79/4885CA1 64/4885 |
| US-20210107915-A1 | CATIONICALLY CURABLE COMPOSITIONS WITH LATENT REDUCING AGENT DEMONSTRATING LOW CURE TEMPERATURE | CHIT1, SGMS2, LTA | ESR1 3732/4885CA12 79/4885CA1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.